Want to join the conversation?
$CMI 2Q15 Call: Revenues were $5Bil, an increase 4% vs. 2Q14. EBIT was $721MMM or 14.4% of sales vs. $657MM or 13.6% in 2Q14, representing an incremental EBIT margin of 36%. Key to these strong results was an improvement in GM of 170 BP YoverY.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)